Early trial tests pill to shrink painful NF1 tumors

This early-stage study is testing the safety and effects of an oral medication called selumetinib in Chinese children and adults with neurofibromatosis type 1 (NF1) who have inoperable plexiform neurofibromas (tumors). Participants take the medication twice daily until their disease worsens or they experience unacceptable side effects. The main goals are to see how the body processes the drug and to monitor for any safety issues, while also checking if the tumors shrink and if pain or quality of life improves.